selected scholarly activity
-
conferences
- 504 Subtle Differences in Commercial Heparins Can Have Serious Consequences for Cardiopulmonary Bypass Patients: a randomized controlled trial. Canadian Journal of Cardiology. S285-S285. 2012
- Comparison between multiplex immunoassay and immunofluorescence methods in detection of anti-nuclear antibodies. Clinical Biochemistry. 783-784. 2010
- Pilot study assessing the utility of an adhesion array and high-sensitivity cytokine array as surrogate biomarkers in ovarian cancer. Clinical Biochemistry. 1271-1271. 2008
- Identification of heparin binding proteins isolated from cell membranes by proteomic analysis. Clinical Biochemistry. 1098-1098. 2006
- Variation in troponin T in stable outpatient hemodialysis patients. Clinical Biochemistry. 1101-1101. 2006
- Pulse Low Dose Steroids Attenuate Post-Cardiopulmonary Bypass SIRS; SIRS I. Journal of Surgical Research. 188-194. 2006
- A comparison of the nonspecific binding of low molecular weight heparin during the three trimesters of pregnancy.. Blood. 649A-649A. 2000
- Comparison of the nonspecific binding of a low molecular of weight heparin (dalteparin) with unfractionated heparin, in pregnant and non-pregnant plasma. Thrombosis and Haemostasis. 532-533. 1999
- Evidence that unfractionated heparin and low molecular weight heparin are eliminated by tubular secretion in the rat kidney. Thrombosis and Haemostasis. 32-32. 1999
- Comparing the in vitro response to heparin in non pregnant and pregnant women.. Blood. 359A-359A. 1998
- Heparin-induced bone loss is not reversible after stopping heparin treatment in rats.. Blood. 358A-358A. 1998
- Vasoflux, a novel anticoagulant that is more effective than heparin and safer than hirudin in rabbits.. Blood. 1316-1316. 1997
- Evidence that vitronectin contributes to non-specific binding of heparin in patient plasma. Thrombosis and Haemostasis. P1222-P1222. 1997
- Vasoflux(TM), a novel oligosaccharide with unique antithrombotic properties. Thrombosis and Haemostasis. P2831-P2831. 1997
- Administration of no-affinity heparin (NAH) in vivo alters the tissue localisation and metabolism of unfractionated heparin (UFH).. Blood. 3510-3510. 1995
- Altered recovery but not clearance contributes to the variation in anticoagulant response to heparin in vivo.. Blood. 3511-3511. 1995
- THE EFFECT OF ANTITHROMBIN-III AND HEPARIN COFACTOR-II CONCENTRATIONS ON THE ANTICOAGULANT ACTIVITIES OF STANDARD AND LOW-MOLECULAR-WEIGHT HEPARIN IN PLASMA. Thrombosis and Haemostasis. 935-935. 1995
- THE EFFECT OF HEPARIN-BINDING PROTEINS ON THE ANTI-THROMBIN ACTIVITY OF UNFRACTIONATED AND LOW-MOLECULAR-WEIGHT HEPARIN IN PLASMA. Thrombosis and Haemostasis. 973-973. 1995
- A COMPARISON OF THE PLASMA RECOVERY OF UNFRACTIONATED HEPARIN WITH THAT OF DERMATAN SULFATE IN PATIENTS WITH THROMBOEMBOLIC DISEASE. Thrombosis and Haemostasis. 657-657. 1993
- DETERMINANTS OF THE ANTITHROMBOTIC RESPONSE TO A STANDARDIZED DOSE OF INTRAVENOUS UNFRACTIONATED HEPARIN IN PATIENTS WITH VENOUS THROMBOEMBOLISM. Thrombosis and Haemostasis. 768-768. 1993
- EX-VIVO COMPARISON OF THE NONSPECIFIC-BINDING OF UNFRACTIONATED HEPARIN AND ENOXAPARIN TO PLASMA-PROTEINS. Thrombosis and Haemostasis. 857-857. 1993
- HEPARIN VARIABILITY AND RESISTANCE - COMPARISONS WITH A DIRECT THROMBIN INHIBITOR. Thrombosis and Haemostasis. 1300-1300. 1993
- THE RECOVERY OF HEPARIN AND HIRUDIN FROM THE PLASMA OF HEPARIN-RESISTANT PATIENTS. Thrombosis and Haemostasis. 659-659. 1993
- HEPARIN BINDING-PROTEINS - POSSIBLE CAUSE OF HEPARIN REBOUND FOLLOWING CARDIOPULMONARY BYPASS. Circulation. 630-630. 1992
- REDUCED BINDING OF LOW-MOLECULAR-WEIGHT HEPARINS TO PLASMA-PROTEINS. Circulation. 869-869. 1992
- GLYCOSAMINOGLYCANS DISPLACE ANTICOAGULANTLY-ACTIVE HEPARIN FROM PLASMA-PROTEIN BINDING-SITES. Thrombosis and Haemostasis. 933-933. 1991
- THE EFFECT OF STORAGE ON PLASMA SAMPLES USED IN HEPARIN ASSAYS. Clinical Chemistry. 975-976. 1990
- EFFECTS OF UNFRACTIONATED HEPARIN, DERMATAN SULFATE AND LOW-MOLECULAR WEIGHT HEPARIN ON VESSEL WALL PERMEABILITY IN RABBITS. HEPARIN AND RELATED POLYSACCHARIDES : STRUCTURE AND ACTIVITIES. 245-254. 1989
-
journal articles
- Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?. Journal of Thrombosis and Thrombolysis. 35:295-301. 2013
- Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery. 144:944-950.e3. 2012
- Intra-individual variability in troponin T concentration in dialysis patients. Clinical Biochemistry. 42:991-995. 2009
- Cytokine elevations in acute coronary syndrome and ovarian cancer: A mechanism for the up-regulation of the acute phase proteins in these different disease etiologies. Clinical Biochemistry. 41:607-610. 2008
- The anti-inflammatory effects of heparin and related compounds. Thrombosis Research. 122:743-752. 2008
- A Systematic Review of Heparin to Treat Burn Injury. Journal of burn care & research : official publication of the American Burn Association.. 28:794-804. 2007
- The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1receptor antagonism ? or inverse agonism ? as potential obesity treatment and other therapeutic use. Journal of Clinical Pharmacy and Therapeutics. 32:209-231. 2007
- Heparin resistance in acute coronary syndromes. Journal of Thrombosis and Thrombolysis. 23:93-100. 2007
- The effects of high-dose heparin on inflammatory and coagulation parameters following cardiopulmonary bypass. Blood Coagulation and Fibrinolysis. 16:323-328. 2005
- Pro: Steroids should be used for cardiopulmonary bypass. Journal of Cardiothoracic and Vascular Anesthesia. 19:250-254. 2005
- Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. European Journal of Cardio-thoracic Surgery. 21:232-244. 2002
- The APTT Response of Pregnant Plasma to Unfractionated Heparin. Thrombosis and Haemostasis. 87:92-97. 2002
- The Binding of Unfractionated Heparin and Low Molecular Weight Heparin to Thrombin-Activated Human Endothelial Cells. Thrombosis Research. 96:373-381. 1999
- A Histomorphometric Evaluation of Heparin-Induced Bone Loss After Discontinuation of Heparin Treatment in Rats. Blood. 93:1231-1236. 1999
- Vasoflux, a New Anticoagulant With a Novel Mechanism of Action. Circulation. 99:682-689. 1999
- The Effects of Standard and Low Molecular Weight Heparin on Bone Nodule Formation In Vitro. Thrombosis and Haemostasis. 80:413-417. 1998
- The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance. Translational Research. 130:649-655. 1997
- Induction of the Acute-Phase Reaction Increases Heparin-Binding Proteins in Plasma. Arteriosclerosis, Thrombosis and Vascular Biology. 17:1568-1574. 1997
- A Histomorphometric Comparison of the Effects of Heparin and Low-Molecular-Weight Heparin on Cancellous Bone in Rats. Blood. 89:3236-3242. 1997
- Effect of Nonspecific Binding to Plasma Proteins on the Antithrombin Activities of Unfractionated Heparin, Low-Molecular-Weight Heparin, and Dermatan Sulfate. Circulation. 95:118-124. 1997
- Differential Sensitivity of Mouse Mononuclear Phagocytes to CSF-1 and LPS: The Potentialin VivoRelevance of Enhanced IL-6 Gene Expression. Cellular Immunology. 174:165-172. 1996
- The Effect of Adding a Surfeit of Autologous CD8+T Cells to SCID Mice after Secondary Rexenografts of Graves' Thyroid Tissue. Thyroid. 6:429-436. 1996
- Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood. 88:1314-1320. 1996
- IL-6 stimulates vitronectin gene expression in vivo.. Journal of Immunology. 155:3180-3185. 1995
- The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood. 86:1368-1373. 1995
- Heparin binding proteins. Contribution to heparin rebound after cardiopulmonary bypass. Journal of Cardiothoracic and Vascular Anesthesia. 8:369-369. 1994
- Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin. Thrombosis and Haemostasis. 71:300-304. 1994
- HEPARIN-BINDING PROTEINS - CONTRIBUTION TO HEPARIN REBOUND AFTER CARDIOPULMONARY BYPASS. Circulation. 88:420-425. 1993
- Heparin binding proteins. Contribution to heparin rebound after cardiopulmonary bypass.. Circulation. 88:II420-II425. 1993
- Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins. Thrombosis and Haemostasis. 70:625-630. 1993
- The Additive Effect of Low Molecular Weight Heparins on Thrombin Inhibition by Dermatan Sulfate. Thrombosis and Haemostasis. 70:443-447. 1993
- Heparin Binding to Plasma Proteins, an Important Mechanism for Heparin Resistance. Thrombosis and Haemostasis. 67:639-643. 1992
- Contribution of Red Blood Cells to the Saturable Mechanism of Heparin Clearance. Thrombosis and Haemostasis. 64:559-563. 1990
- Effects of Unfractionated Heparin, Dermatan Sulfate and Low Molecular Weight Heparin on Vessel Wall Permeability in Rabbitsa. Annals of the New York Academy of Sciences. 556:245-254. 1989
- Use of a competitive inhibitor in a kinetic enzymatic method for measuring ethanol in serum.. Clinical Chemistry. 33:2296-2298. 1987
- Asymmetric distribution of sites with high affinity for antithrombin III in rat skin heparin proteoglycans.. Journal of Biological Chemistry. 257:8749-8754. 1982
- The assay and partial characterization of macromolecular heparin depolymerase activity in rat small intestine. Biochemical Journal. 180:587-596. 1979